Cigna’s PT Cut to $370 and CEO Transition Signal Margin Risks
Piper Sandler cut Cigna’s price target to $370 from $374 but kept an Overweight rating, citing its rebate-free PBS model’s compliance with the 2026 Appropriations Act and FTC settlement. CEO David Cordani will retire July 1, succeeded by Brian Evanko, as the rebate-free shift is set to pressure margins.
1. Piper Sandler Lowers Price Target
Piper Sandler reduced Cigna’s price target to $370 from $374 while maintaining an Overweight rating, emphasizing the strategic importance of its rebate-free pharmacy benefit services (PBS) model. The firm highlighted this model’s alignment with the 2026 Appropriations Act and FTC settlement as a risk mitigation factor supporting potential valuation expansion.
2. CEO David Cordani Retirement and Succession
Long-serving CEO David Cordani, age 60 and in the role since 2009, will retire on July 1 and transition to executive chair. He will be succeeded by Brian Evanko, 49, who has spent three decades at Cigna and currently oversees Cigna Healthcare and Evernorth Health Services.
3. Shift to Rebate-Free PBS Model and Margin Outlook
Cigna is moving customers to a rebate-free structure that eliminates after-market discounts, a change expected to weigh on margins over the next two years. Management argues the approach could reshape public perception of pharmacy benefit managers and reduce long-term growth risks for the PBS business.